Anika Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Anika Therapeutics (ANIK) Tops Q1 EPS by 12c; $50M Buyback
May 2, 2019 4:43 PM EDTAnika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of $0.31, $0.12 better than the analyst estimate of $0.19. Revenue for the quarter came in at $24.7 million versus the consensus estimate of $21.88 million.
Announces $50 Million Share Repurchase Program.
Anika is off to a strong start in 2019, with double-digit... More
